Marginal-Zone Lymphomas The third most common lymphoma, MZL is usually indolent and
often a consequence of chronic antigenic stimulation from a pathogen such as Helicobacter …

Patients with cancer are poorly represented in coronavirus disease 2019 (COVID-19) series,
and heterogeneous series concerning hematology patients have been published. This study …

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell
therapy against that of the previous standard of care (SOC) for refractory large B-cell …

Follicular lymphoma, the most common indolent lymphoma, originates from germinal centre
B-cells of the lymphoid follicle, and is characterized by t (14; 18). Clinical manifestations …

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how
EZH2 affects patients' response to therapy. In this context, the aim of this study was to …

Although follicular lymphoma (FL) patients relapsing within 24 months after first‐line
treatment (POD24) have a poor prognosis, some cases show notable survival after first …

Abstract The Prognostic Nutritional Index (PNI), a parameter combining serum albumin
concentration and absolute lymphocyte count, is considered a measure of the nutritional and …

Although next-generation sequencing (NGS) data on lymphomas require further validation
before being implemented in daily practice, the clinical application of NGS can be …

Simple Summary An increased risk of hematological malignancies, mainly lymphomas, has
been described in patients with inflammatory bowel disease (IBD). Because there are scarce …

Simple Summary CAR T therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel
(tisa-cel) have been approved in Spain for patients with relapsed/refractory (R/R) diffuse …